|
Allo Transplantation with Mylotarg, fludarabine and melphalan for AML, CML and MDS. Clinical Trials Information presented on Clinical Trials Search is not intended to be a substitute for qualified health advice, trips or treatment by using a genuine doctor. We aren't doctors. Always consult your mD on Allo Transplantation with Mylotarg, fludarabine and melphalan for AML, CML and MDS. conditions. Clinical Trials Search.org is a site committed to listing clinical research studies in human subjects. Allo Transplantation with Mylotarg, fludarabine and melphalan for AML, CML and MDS. Clinical research trials and Allo Transplantation with Mylotarg, fludarabine and melphalan for AML, CML and MDS. health trials take place in a lot of of cities across the US. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally measure the potency of new drugs. The aim of the studies / projects is to answer specific human medical questions. Clinical trials are a popular manner for physicians, government agencies, and private sector corporations to discover remedies for all kinds of circumstances, like Allo Transplantation with Mylotarg, fludarabine and melphalan for AML, CML and MDS.. Allo Transplantation with Mylotarg, fludarabine and melphalan for AML, CML and MDS. Clinical Trials and other clinical trials allow for volunteers to have health treatment alternatives before they are available to the general public. Many times the test subjects obtain treatment for without cost, and occasionally they are paid for their time. Sometimes there is a cost for a Allo Transplantation with Mylotarg, fludarabine and melphalan for AML, CML and MDS. clinical trial. Subjects oftentimes recieve the most effective healthcare possible for their Allo Transplantation with Mylotarg, fludarabine and melphalan for AML, CML and MDS. condition. Hazards are a reality, however, and could include additional or frequent doctor visits, healthcare dangers (perhaps life-threatening), and/or the treatment being ineffective. Trials are federally governed with exacting guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "A" Clinical Trials Conditions > Allo Transplantation with Mylotarg, fludarabine and melphalan for AML, CML and MDS.  Allo Transplantation with Mylotarg, fludarabine and melphalan for AML, CML and MDS.
Allo Transplantation with Mylotarg, fludarabine and melphalan for AML, CML and MDS.
For Condition: Chronic Lymphocytic Leukemia,Myelodysplastic Syndrome,Acute Myelogenous Leukemia
Status: Recruiting
Sponsor(s): M.D. Anderson Cancer Center ,
Synopsis: Primary Objective: To determine the safety and maximum tolerated dose of Mylotarg as part of a reduced-intensity preparative regimen patients undergoing related, mismatched-related or matched unrelated donor transplantation. Secondary Objectives: 1. To evaluate response rates, engraftment kinetics and degree of chimerism achievable with this strategy. 2. To evaluate the incidence and severity of GVHD in this population 3. To evaluate disease-free and overall survival and relapse rates.
Details: Allogeneic bone marrow transplantation is an effective first line and salvage therapy in-patients with AML, CML or MDS. In the past, allogeneic transplantation has been limited to younger patients due to the increased risk of regimen-related toxicity and graft-versus-host disease (GVHD). In order to expand the use of alloBMT to older patients, researchers at MD Anderson Cancer Center have pioneered the use of nonmyeloablative preparative therapy for allogeneic transplantation. Nonmyeloablative therapy utilizes low-dose chemotherapy in order to decrease regimen-related toxicity. The low-dose chemotherapy induces host immunosuppression, spares toxicity, and allows engraftment of donor stem cells. The goal of this therapy is to exploit the anti-tumor effects of donor immune cells. One shortcoming of nonmyeloablative transplantation is an increased risk of disease relapse, especially in patients with high-risk disease. This includes patients with relapse or refractory AML, advanced MDS and advanced CML. Mylotarg is a novel immunotoxin directed against the CD33 antigen found on most AML, CML and MDS clones. Mylotarg has been shown to have significant anti-leukemia activity with little toxicity. The goal of this Phase I/II protocol is to evaluate the safety and efficacy of adding escalating doses of Mylotarg to Fludarabine and Melphalan in patients with CML, MDS or acute myelogenous leukemia undergoing related, mismatch-related or matched unrelated donor allogeneic transplantation. The hypothesis is that Mylotarg will provide potent anti-leukemic effects without additional toxicity. Mylotarg, Melphalan, and Fludarabine have non-overlapping toxicities. A more potent anti-leukemic response may increase the complete remission rates and induce a state of minimal residual disease (MRD). Therefore, the GVL effect will have a better chance for success.
Eligibility:
Study Type: Interventional, Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study
Minimum Age/Maximum Age: 55 Years/75 Years
Genders: Both
Protocol Entry Criteria: Inclusion Criteria: - Patients 12-75 years of age - Patients are eligible if deemed ineligible for conventional high dose chemotherapy programs because of concurrent medical conditions. Patients with refractory AML are always eligible if ejection fraction > 35, FEV1, FVC, or DLCO > 40%, abnormal LFT's. - Patients must have recovered from previous Grade III-IV toxicity due to prior anti-neoplastic therapy (except alopecia). - Patients with the following disease categories will be eligible: a. AML with induction failure, relapse or 2nd remission b. MDS with IPI INT-2 or High-risk disease (Appendix 4) or CMML c. CML in accelerated phase or blast crisis d. Interferon or STI resistant CML not eligible for conventional stem cell transplant - Patients receiving prior BMT are eligible. If myeloablative chemoradiotherapy was used in the prior transplant patients must be >90 days from transplant. If non-myeloablative therapy was used patients must be >30 days post-transplant. - Leukemia cells must express cell surface CD33 evaluated by flow cytometry in > 20% of leukemia cells. - Patients must have an HLA-compatible related donor (6/6 or 5/6 HLA-match) capable of donating bone marrow or G-CSF stimulated peripheral blood stem cells using aphereses techniques or a 6/6 HLA matched unrelated bone marrow donor (serologic matching for Class I, molecular matching for DR?1). - Patients must have a ECOG PS<2 (Appendix 6), Cr<2.0, bilirubin <2, and (SGPT) <3x normal - Patients must have an estimated life expectancy > 3 months - Patient and donor must sign informed consent. Unrelated donors will be consented according to the National Donor Marrow Registry policy Exclusion Criteria: - uncontrolled active infection - HIV disease - pregnancy and nursing - active, uncontrolled CNS leukemia
Total Enrollment: 44
Location and Contact Information:
MD Anderson Cancer Center *Recruiting*
Houston, Texas, 77030
United States
Recruiting Gloria McCormick 713-745-1721
Additional Information:
Study ID Numbers: ID01-010;
Study Start Date: May 2001
Record last reviewed: January 2004
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00038831
Other Myelodysplastic Syndrome Studies:
1. Combination Antibody Therapy for Relapsed Lymphoma and Chronic Lymphocytic Leukemia
2. Autologous T Cell Immunotherapy for Chronic Lymphocytic Leukemia (CLL) Patients
3. Donor Th2 Cells to Prevent Graft-Versus-Host Disease in Bone Marrow Transplants
4. Tipifarnib in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
5. Pentostatin, Cyclophosphamide, and Rituximab in Treating Patients With Chronic Lymphocytic Leukemia or Other B-cell Cancers
Related Studies:
Other Myelodysplastic Syndrome Clinical Trials
Other Texas Clinical Trials
Other Houston Clinical Trials
Allo Transplantation with Mylotarg, fludarabine and melphalan for AML, CML and MDS.
|
|
|
|
|
|
|
|
